glp-1 alcohol reduction Anti-Obesity Rx and and Substance Use Disorders IUPHAR review – Glucagon-like peptide-1
Description
Use of antihyperglycemic drugs and risk of cancer in patients with diabetes
Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)
Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients
In November 2023, AstraZeneca and Eccogene signed an exclusive license agreement for ECC5004, an investigational oral once-daily GLP-1RA for treating obesity, type 2 diabetes, and other cardiometabolic conditions
They have asked for the consolidation in the same court (Pennsylvania Federal Court) and judge (Karen M
